Hypoxia-activated ROS burst liposomes boosted by local mild hyperthermia for photo/chemodynamic therapy

Tang, Xianglong; Wang, Zhen; Zhu, Yun-yang; Xiao, Hong; Xiao, Yong; Cui, Sheng; Lin, Benlan; Yang, Kun; Liu, Hongyi

doi:10.1016/j.jconrel.2020.08.035

Cited by 48 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, high levels of ROS could exert detrimental effects to tumor cells. As a matter of factor, chemotherapy and radiotherapy usually increase the ROS generation in tumor cells and make use of ROS-induced damage to kill the tumor cells ( Kou et al, 2020b ; Tang et al, 2020 ; Yang et al, 2020 ). It has been reported that ALA could induce apoptosis through upregulating ROS production along with GSH depletion in various cancers ( Wang et al, 2018 ; Xu et al, 2019b ; Yin et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Bao

Zheng

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the most common malignancies and also a leading cause of cancer-related mortality worldwide. Many studies have shown that epidermal growth factor receptor (EGFR) is highly expressed in PC, which provides a potential target for PC treatment. However, EGFR inhibitors use alone was proven ineffective in clinical trials, due to the persistence of cellular feedback mechanisms which foster therapeutic resistance to single targeting of EGFR. Specifically, the signal transducer and activator of transcription 3 (STAT3) is over-activated when receiving an EGFR inhibitor and is believed to be highly involved in the failure and resistance of EGFR inhibitor treatment. Therein, we hypothesized that dual inhibition of EGFR and STAT3 strategy could address the STAT3 induced resistance during EGFR inhibitor treatment. To this end, we tried to develop poly (lactic-co-glycolic acid) (PLGA) nanoparticles to co-load Alantolactone (ALA, a novel STAT3 inhibitor) and Erlotinib (ERL, an EGFR inhibitor) for pancreatic cancer to test our guess. The loading ratio of ALA and ERL was firstly optimized in vitro to achieve a combined cancer-killing effect. Then, the ALA- and ERL-co-loaded nanoparticles (AE@NPs) were successfully prepared and characterized, and the related anticancer effects and cellular uptake of AE@NPs were studied. We also further detailly explored the underlying mechanisms. The results suggested that AE@NPs with uniform particle size and high drug load could induce significant pancreatic cancer cell apoptosis and display an ideal anticancer effect. Mechanism studies showed that AE@NPs inhibited the phosphorylation of both EGFR and STAT3, indicating the dual suppression of these two signaling pathways. Additionally, AE@NPs could also activate the ROS-p38 axis, which is not observed in the single drug treatments. Collectively, the AE@NPs prepared in this study possess great potential for pancreatic cancer treatment by dual suppressing of EGFR and STAT3 pathways and activating ROS-responsive p38 MAPK pathway.

show abstract

Section: Resultsmentioning

confidence: 99%

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Bao

Zheng

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… Combination therapy Nanomedicine PTA Major effects of mPTT Ref. RT Multimodal bioimaging-guided nanomedicine Gd3 + -doped WS 2 Improve tumor oxygenation [111] Core-shell nanomedicine Ti 3 C 2 @Au [112] Bi 2 Se 3 hollow nanocubes (HNC-s-s-HA/GA) Bi 2 Se 3 Raise blood flow [33] Platinum nanoworm Pt [113] PDT Nucleic-acid-driven activatable nanotheranostics Phthalocyanine photosensitizer (PcS) Enhance tumor oxygenation [114] Zr-FeP MOF MOF Increase ROS production [44] Lyp-1 modified docetaxel/IR820 co-loaded micelles IR820 [115] Hypoxia-activated ROS burst liposomes Ce6 [116] Up-conversion nanoparticle Fe 3+ doped MOFs [117] Pd@Pt-PEG-Ce6 Pt Trigger H 2 ...…”

Section: Nanomedicine-promoted Synergistic Therapies For Optimizing Mpttmentioning

confidence: 99%

“…Mild heat could elevate temperature at tumor site to accelerate Fenton reaction tumor-specifically, enhancing the antitumor effect of CDT. Tang et al designed superparamagnetic iron oxide nanoclusters (SPIOCs) to acquire superior Fenton catalyst activity and high PCE [116] . Moreover, chlorin e6, a well-studied photosensitizer was carried on SPIOCs and the complex was further stabilized by hypoxia-responsive poly (metronidazole) liposomes to generate a hypoxia-activated ROS burst nanoparticle.…”

Section: Nanomedicine-promoted Synergistic Therapies For Optimizing Mpttmentioning

confidence: 99%

Nanomedicine potentiates mild photothermal therapy for tumor ablation

Jiang

Cheng

et al. 2021

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

The booming photothermal therapy (PTT) has achieved great progress in non-invasive oncotherapy, and paves a novel way for clinical oncotherapy. Of note, mild temperature PTT (mPTT) of 42–45 °C could avoid treatment bottleneck of the traditional PTT, including nonspecific injury to normal tissues, vasculature and host antitumor immunity. However, cancer cells can resist mPTT via heat shock response and autophagy, thus leading to insufficient mPTT monotherapy to ablate tumor. To overcome the deficient antitumor efficacy caused by thermo-resistance of cancer cells and mono mPTT, synergistic therapies towards cancer cells have been conducted with mPTT. This review summarizes the recent advances in nanomedicine-potentiated mPTT for cancer treatment, including strategies for enhanced single-mode mPTT and mPTT plus synergistic therapies. Moreover, challenges and prospects for clinical translation of nanomedicine-potentiated mPTT are discussed.

show abstract

“…Additionally, COL5A1 was also reported to be a hypoxia-related gene [ 8 ]. Hypoxia is known to trigger the production of reactive oxygen species [ 9 ], which play an important role in cancer biology. Collagen deposition is often regarded as a pathological characteristic in tumor microenvironment [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors

Zhu

Shan

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. Collagen type V alpha 1 chain (COL5A1) is a hypoxia-related gene (a collagen family protein) and participates in the formation of the extracellular matrix. Although some evidence supports a significant role for COL5A1 in the progression of several cancers, a pan-cancer analysis of COL5A1 is not currently available. Herein, we aimed to assess the prognostic value of COL5A1 in 33 human cancers and to investigate its underlying immunological function. Methods. Through multiple bioinformatics methods, we analyzed the data from Oncomine, TCGA, CCLE, HPA, DNMIVD, and cBioPortal database to explore the potential underlying carcinogenic effect of COL5A1, including the relevance of COL5A1 to the outcome, DNA methylation, tumor microenvironment, immune cells infiltration, and drug sensitivity in 33 human cancers. The effects of COL5A1 on glioma cell proliferation, migration, and invasion were verified in cellular experiments. Results. Our findings indicated that COL5A1 was expressed at high levels in 13 cancers and was negatively related to the prognosis of 11 cancers. Additionally, COL5A1 was coexpressed with genes encoding the major histocompatibility complex, immune activators, immune suppressors, chemokines, chemokine receptors, mismatch repair genes, and immune checkpoints. We also identified different roles for COL5A1 in the immunocyte infiltration in different cancers. The correlation between COL5A1 and drug sensitivity was found in several cancers. COL5A1 potentially influenced the tumor progression through immune-related pathways, negative regulation of immune system processes, chemokine signaling pathways, JAK-STAT pathways, T cell receptor pathways, lymphocyte migration, and antigen processing and presentation, among other processes. Conclusions. Based on our study, COL5A1 may be employed as a prognostic marker in different malignancies because of its impact on tumorigenesis and immune cell infiltration and have implications for cancer immune checkpoint inhibitors and chemotherapy.

show abstract

Hypoxia-activated ROS burst liposomes boosted by local mild hyperthermia for photo/chemodynamic therapy

Cited by 48 publications

References 43 publications

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Nanomedicine potentiates mild photothermal therapy for tumor ablation

The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors

Contact Info

Product

Resources

About